Decoding Wegovy® Doses: Finding Your Optimal Path to Lasting Weight Management

Last reviewed: June 27, 2026

Last updated: June 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Wegovy is not dosed at a single strength; the labeling describes a stepped escalation that reaches maintenance over roughly four months, and the strengths involved have expanded meaningfully in the past year. According to the Wegovy prescribing information, the injection is supplied as single-dose pens in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and 7.2 mg (Wegovy HD) presentations, and the label now also covers Wegovy tablets in 1.5 mg, 4 mg, 9 mg, and 25 mg. What follows is a description of what that labeling says and why it is structured the way it is. It is not a schedule for you to follow. Which strengths apply to you, in what sequence, and for how long is a determination your prescriber makes and your pharmacy label records.

What the Label Describes

The Wegovy labeling states that "the recommended starting dosage of WEGOVY injection is 0.25 mg administered subcutaneously once weekly," and directs prescribers to follow a dosage escalation table "to reduce the risk of gastrointestinal adverse reactions." That table moves through 0.25 mg, 0.5 mg, 1 mg, and 1.7 mg in successive four-week blocks before reaching maintenance from week 17 onward.

Two features of that structure are worth noticing. First, the escalation exists for tolerability, not because lower strengths are ineffective placeholders. Second, the label is explicit that the schedule is not rigid: "if patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks." Flexibility is written into the labeling, and exercising it is a clinical decision.

Why Escalation Exists at All

The most common adverse reactions to semaglutide are gastrointestinal — nausea, vomiting, diarrhea, constipation, abdominal discomfort. These are generally dose-related and tend to be most pronounced when exposure is rising. Starting low and stepping up gives the gastrointestinal tract time to adapt while blood levels climb toward a new steady state.

There is a pharmacokinetic reason the steps are four weeks apart rather than one. Semaglutide has an elimination half-life of approximately one week, and steady-state exposure is reached after roughly four to five weeks of once-weekly dosing. A shorter interval would mean escalating before the previous strength had actually shown what it does. That is also why judging a strength after a single week tells you very little.

The 7.2 mg Addition Changed the Top of the Range

For most of Wegovy's history, 2.4 mg once weekly was the labeled maximum. That is no longer the case. The current label includes a higher-dose presentation, Wegovy HD, and describes a maximum dosage of 7.2 mg subcutaneously once weekly for weight reduction in adults, reserved for patients who have tolerated 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated.

The supporting trial, STEP UP, ran 72 weeks in 1,407 participants and reported mean weight change of −18.7% at 7.2 mg versus −15.6% at 2.4 mg and −3.9% with placebo. That is a real incremental difference, and it is also a reminder that dose escalation past maintenance is a clinical judgment about benefit versus tolerability — not a default next step, and not something to request because a number is larger.

Wegovy Tablets Follow a Completely Different Structure

The tablets are not a pill version of the weekly schedule. The label describes a starting dosage of 1.5 mg taken orally once daily, with escalation at 30-day intervals through 4 mg and 9 mg to a maintenance dosage of 25 mg orally once daily. Daily rather than weekly, milligram figures that are not comparable to the injection's, and a different escalation cadence.

The indications differ too. Wegovy injection is indicated for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, for weight reduction in adults and pediatric patients aged 12 and older, and for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. The tablets carry only the cardiovascular risk reduction and adult weight reduction indications. Same molecule, different labeled scope.

Dose Is Not the Same Thing as Response

The trial data make it clear that reaching a particular strength does not deliver a particular result. In STEP 1, which ran 68 weeks, mean weight change was −14.9% with semaglutide 2.4 mg versus −2.4% with placebo. Those are group averages around which individual outcomes varied enormously — some participants far exceeded them, some fell well short, at the same dose.

This is why "what dose should I be on" is usually the wrong question and "how is this working for me" is the right one. The labeled ladder is a tolerability framework, not a performance dial. A prescriber weighing whether to escalate is looking at your response, your side effects, your other conditions, and your goals together — a judgment no article can make in advance.

Maintenance Is the Part That Actually Determines Outcomes

The evidence on stopping is unambiguous. In the STEP 4 randomized withdrawal trial, 902 participants completed a 20-week run-in and 803 who reached 2.4 mg weekly were randomized 2:1 to continue or switch to placebo. From week 20 to week 68, those continuing lost a further 7.9% of body weight while those switched to placebo regained 6.9% — a difference of 14.8 percentage points.

The STEP 1 trial extension followed 327 participants for a year after all treatment stopped. Mean weight loss on semaglutide had been 17.3%; one year off treatment, participants had regained approximately two-thirds of it, ending at a net 5.6% below baseline, with cardiometabolic variables moving in parallel. The authors concluded that ongoing treatment is required to maintain the improvements. "Lasting" weight management, in other words, is a question about the plan after the ladder — not about the top rung.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

What strengths does Wegovy come in?

The prescribing information lists single-dose injection pens in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and 7.2 mg, the last marketed as Wegovy HD. The same label now also covers Wegovy tablets in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths. Which of these applies to any individual is determined by their prescriber, not by the range of strengths available.

How long does it take to reach the maintenance dose?

The labeled escalation for the injection moves through four-week blocks, reaching maintenance from week 17 onward — roughly four months. The label also states that if a patient does not tolerate a dose during escalation, prescribers should consider delaying escalation for four weeks. Individual timelines therefore vary, and yours is set by your prescriber and recorded on your pharmacy label.

Is 7.2 mg better than 2.4 mg?

In the STEP UP trial, which ran 72 weeks in 1,407 participants, mean weight change was −18.7% at 7.2 mg versus −15.6% at 2.4 mg and −3.9% with placebo. The label reserves the higher dosage for adults who have tolerated 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated. Whether it is appropriate for a given person is a clinical judgment.

How do Wegovy tablets compare to the injection?

They follow an entirely different structure: 1.5 mg orally once daily to start, escalating at 30-day intervals through 4 mg and 9 mg to a 25 mg daily maintenance dosage. The milligram figures are not comparable to the weekly injection. The tablets also carry a narrower set of indications, covering cardiovascular risk reduction and adult weight reduction only.

What happens to weight after stopping?

In the STEP 1 trial extension, 327 participants were followed for a year after treatment stopped. Mean weight loss on semaglutide had been 17.3%, and participants regained roughly two-thirds of it, ending at a net 5.6% below baseline, with cardiometabolic measures moving in parallel. In the STEP 4 withdrawal trial, those switched to placebo regained 6.9% between weeks 20 and 68.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.